Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid LeukemiaHEHLMANN, Rüdiger; LAUSEKER, Michael; HÄNEL, Mathias et al.Journal of clinical oncology. 2011, Vol 29, Num 12, pp 1634-1642, issn 0732-183X, 9 p.Article

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IVSAUSSELE, Susanne; LAUSEKER, Michael; SCHLIMOK, Günter et al.Blood. 2010, Vol 115, Num 10, pp 1880-1885, issn 0006-4971, 6 p.Article